Home - SelectION, Inc.

with superior selectivity and specificity

Therapeutic peptides

toxins of venomous animals

Derived from evolutionary tuned

which selectively

Peptide drugs

target ion channels

for autoimmune patients

Improving quality of life

Targeting Ion Channels

MORE

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

May 9, 2022

Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality – San Diego, CA, USA, and Munich, Germany – May 09, 2022 – selectION, Inc., a biopharmaceutical company developing novel peptide therapies…

Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22^nd to 24^th, 2022

January 11, 2022

SAN DIEGO, January 11, 2022 – Meet Antonius Schuh, Ph.D. (CEO), Andreas Klostermann, Ph.D. (CSO) and Steve Zaniboni (CFO) for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.

with superior selectivity and specificity

Therapeutic peptides

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22^nd to 24^th, 2022

About

Recent News

Contact

with superior selectivity and specificity

Therapeutic peptides

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

selectION, Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development

Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22nd to 24th, 2022

About

Recent News

Contact

Meet selectION, Inc. at the Biocom’s 2022 Global Life Science Partnering Conference in San Diego on February 22^nd to 24^th, 2022